BioPharmSignal logoBioPharmSignal

Biotech News

LENZ Therapeutics to Participate in Upcoming Investor Conferences

Lenz Therapeutics Inc (LENZ)Lenz Therapeutics IncCompany update

LENZ (LENZ) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is lenz.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

LENZLenz Therapeutics Inc2026-05-04 12:00 EST

LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference

LENZLenz Therapeutics Inc2026-08-04 20:05 EST

LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026

OCGNOcugen2026-07-31 11:02 EST

Ocugen to Participate in Upcoming August Investor Conferences

OCGNOcugen2026-06-02 11:03 EST

Ocugen to Participate in Upcoming June Investor and Industry Conferences

TARSTarsus Pharmaceuticals2026-05-28 20:30 EST

Tarsus to Participate in Upcoming Investor Conferences

BLTEBelite Bio2026-04-23 12:00 EST

Belite Bio to Participate in Four Upcoming Investor Conferences

OCSOculis2026-04-07 08:00 EST

Oculis to Participate in Upcoming Investor Conferences

OCULOcular Therapeutix2026-07-01 11:00 EST

Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences

OKYOOKYO Pharma2026-04-29 11:00 EST

OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May

OCULOcular Therapeutix2026-04-27 11:00 EST

Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences

View all latest news

Lenz Therapeutics Inc

Presbyopia-Focused Company LENZ Therapeutics is an ophthalmic pharmaceutical company focused on pharmacologic treatment of presbyopia, the age-related loss of near vision. VIZZ VIZZ is an aceclidine ophthalmic solution designed to improve near vision through pupil modulation while limiting accommodative stimulation. It is the company's...

Recent company news

LENZLenz Therapeutics Inc2026-08-04 20:05 EST

LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026

LENZLenz Therapeutics Inc2026-07-06 12:15 EST

LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia

LENZLenz Therapeutics Inc2026-06-24 12:30 EST

LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand

LENZLenz Therapeutics Inc2026-06-07 23:30 EST

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

LENZLenz Therapeutics Inc2026-05-26 12:00 EST

LENZ Therapeutics to Participate in Upcoming Investor Conferences

Stock data

Close
5.22 USD
Market cap
223.56M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States